文献速递基础与转化研究临床试验与 GCP

全人源结合域抗CD19 CAR T细胞治疗B细胞淋巴瘤的安全性与可行性

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
PubMed 文献 · Nat Med · 2020-01-20

一项I期首次人体临床试验纳入20例B细胞淋巴瘤患者,评估表达全人源抗CD19 CAR Hu19-CD828Z的T细胞的安全性与可行性。

要点

  • 严重神经毒性仅5%,显著低于FMC63-28Z的50%(P=0.0017)。
  • 细胞因子释放水平更低,可能解释神经毒性降低。

核心结论

  • Hu19-CD828Z CAR T细胞治疗B细胞淋巴瘤安全可行,抗淋巴瘤活性与FMC63-28Z相似但严重神经毒性显著更低。

研究设计与样本

  • I期首次人体临床试验(NCT02659943),纳入20例B细胞淋巴瘤患者,主要目的为评估Hu19-CD828Z T细胞治疗的安全性与可行性。

主要发现

  • Hu19-CD828Z T细胞的抗淋巴瘤活性与表达FMC63-28Z的T细胞相似。
  • 接受Hu19-CD828Z T细胞的患者严重神经毒性发生率为5%,而接受FMC63-28Z T细胞的患者为50%(P=0.0017)。
  • Hu19-CD828Z T细胞释放的细胞因子水平低于FMC63-28Z T细胞,患者血中细胞因子水平也更低。
  • CAR T细胞释放的细胞因子水平尤其取决于CAR设计中的铰链区和跨膜结构域。

临床怎么用

  • 全人源结合域CAR设计可能降低神经毒性,同时保持抗淋巴瘤活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells are an effective treatment for B-cell lymphoma, but often cause neurologic toxicity. We treated 20 patients with B-cell lymphoma on a phase I, first-in-human clinical trial of T cells expressing the new anti-CD19 CAR Hu19-CD828Z (NCT02659943). The primary objective was to assess safety and feasibility of Hu19-CD828Z T-cell therapy. Secondary objectives included assessments of blood levels of CAR T cells, anti-lymphoma activity, second infusions and immunogenicity. All objectives were met. Fifty-five percent of patients who received Hu19-CD828Z T cells obtained complete remission. Hu19-CD828Z T cells had clinical anti-lymphoma activity similar to that of T cells expressing FMC63-28Z, an anti-CD19 CAR tested previously by our group, which contains murine binding domains and is used in axicabtagene ciloleucel. However, severe neurologic toxicity occurred in only 5% of patients who received Hu19-CD828Z T cells, whereas 50% of patients who received FMC63-28Z T cells experienced this degree of toxicity (P = 0.0017). T cells expressing Hu19-CD828Z released lower levels of cytokines than T cells expressing FMC63-28Z. Lower levels of cytokines were detected in blood from patients who received Hu19-CD828Z T cells than in blood from those who received FMC63-28Z T cells, which could explain the lower level of neurologic toxicity associated with Hu19-CD828Z. Levels of cytokines released by CAR-expressing T cells particularly depended on the hinge and transmembrane domains included in the CAR design.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020. PMID: 31959992. doi:10.1038/s41591-019-0737-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。